Business Wire

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers

12.5.2022 09:00:00 EEST | Business Wire | Press release

Share

Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005724/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers (Photo: Business Wire)

The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.

Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.

The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.

Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: “Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector.”

Hiroki Itou, President of Crown Bioscience & MBL commented: “Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan.”

###

About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities in the US, Europe and Asia. Find out more: www.crownbio.com.

About Medical & Biological Laboratories Co., Ltd.
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries:
Crown Bioscience
Louise Stenson
pr@crownbio.com

Medical & Biological Laboratories
Youichi Kozuka
kouhou@mbl.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Historic French Luxury Leather Goods House Moreau Paris Sold to Leading Manufacturer3.8.2026 12:00:00 EEST | Press release

ASTEREN announces that the Paris Commercial Court has approved the acquisition of Moreau Paris, one of France’s most prestigious luxury leather goods houses, by Cardinal Invest, owner of the French luxury manufacturer Groupe Lécuyer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803029803/en/ Paris flagship rue du Faubourg Saint-Honoré (source: Moreau Paris) The transaction concludes a competitive international sale process conducted under the supervision of the Paris Commercial Court and marks the beginning of a new chapter for one of the last independent historic Paris monogram houses. Led by judicial liquidator Pablo Castanon at ASTEREN, with Richard Morgan Advisory as financial advisor, the process launched in early June attracted substantial interest from trade and financial investors worldwide. The Court order signed on 29 July lays the foundations for renewed investment, international expansion and long-term indus

Kioxia to Showcase CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series for AI Workloads3.8.2026 11:22:00 EEST | Press release

Kioxia Corporation, a world leader in memory solutions, today announced that it will exhibit the KIOXIA XL1 series, a Compute Express Link™ (CXL™) compatible memory expansion module, at the Kioxia booth at FMS: the Future of Memory and Storage, taking place August 4 - 6 in Santa Clara, CA. The product features KIOXIA XL-FLASH™, a low-latency and high-performance flash memory technology that enables flash memory, traditionally used for storage applications, to also be utilized as a memory expansion solution. In addition, it is being designed and developed to support the growing volume of memory-intensive AI applications. Evaluation samples are scheduled to be shipped to industry ecosystem collaborators in August 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803920975/en/ CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series In recent years, the growing number of AI workloads has significantly increased memory de

Leading Data Centre Operator CEO Announced for Data Center World Europe Keynote3.8.2026 10:00:00 EEST | Press release

Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, today announces Svein Alte Hagaseth, Founder and CEO, Heim Datacenter will deliver the opening keynote. A recognised industry leader, Svein spent a decade at Green Mountain in several leadership roles, including CEO, scaling the business from regional challenger to global leader. He is now Founder and CEO of Heim Datacenter, a Nordic platform developing scalable, sustainable infrastructure for hyperscale, high-performance computing. Bill Kleyman, Executive Chair, Data Center Programs, Data Center World/CEO and Co-Founder, Apolo will be joining the keynote as moderator. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It is co-located with the leading global network infrastructure event Network X. Register fo

Energy Impact Partners Expands Nordic Investment Presence, Deepening Partnership with Nysnø Climate Investments3.8.2026 09:02:00 EEST | Press release

Energy Impact Partners LP ("EIP"), a global investment firm with over $5 billion in assets under management, today announced an expanded commitment to the Nordic energy innovation ecosystem, building on its longstanding strategic partnership with Nysnø Climate Investments ("Nysnø"). The expansion reflects EIP's conviction that Norway and the broader Nordic region will be a defining source of next-generation energy companies. It also marks a deepening of the firm's institutional relationship with Nysnø, an investor in EIP's $1.36 billion flagship fund. Together, the two firms aim to strengthen connectivity between Nordic founders and EIP's global network spanning venture capital, private equity, and credit. "Norway is one of the most sophisticated and forward-looking energy markets in the world," said Matthias Dill, CEO & Managing Partner, Europe at EIP. "We believe many of the defining companies of the next energy economy will emerge from ecosystems like Norway, where deep technical ex

First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye